A Study to Assess TTI-0102 vs Placebo in MELAS Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Assess TTI-0102 vs Placebo in MELAS Patients — Stella

Home/MELAS Syndrome/

View on ClinicalTrials.gov

Recruiting

Back to MELAS Syndrome trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

France

Angers University Hospital Center (CHU Angers), Angers

Netherlands

Radboud University Medical Center, Nijmegen

Key details

Phase

Safety & dosing

Sponsor

Thiogenesis Therapeutics, Inc.

Enrollment target

~12 participants

Started

May 2025

Primary completion

April 2026

Age range

16 Years – 60 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.